Skip to main content
. Author manuscript; available in PMC: 2013 May 1.
Published in final edited form as: Mol Cancer Ther. 2012 Aug 14;11(11):2535–2540. doi: 10.1158/1535-7163.MCT-12-0163

Table 1.

Clinicopathologic findings for patients with EGFR-mutant adenosquamous carcinomas. The majority were diagnosed with squamous cell carcinoma in at least 1 sample.

Patient# Age Gender Race Smoking Stage Biopsy #1^ Biopsy #1 Mutation Biopsy #2^ Biopsy #2 Mutation Lines of therapy EGFR TKI line Best response to EGFR TKI TTP on
TKI(months)
OS (months)
1 (1) 61 M White Never IV Squamous (L1) exon 19 del Adenosquamous (LLL lung) exon 19 del 3 2nd line PR 12.1 27.5
2 (2) 71 F White Never IV Squamous (RLL lung) exon 19 del Adenocarcinoma (RLL lung) exon 19 del 2 1st line Unavailable 19.6 32.9+
3 (3) 58 F White Never IV Squamous (RUL lung) exon 19 del Adenosquamous (LLL lung) exon 19 del 3 2nd line SD 23.6 32.2+
4 (4) 45 F Hispanic Never IV Squamous (sacrum) exon 19 del Adenocarcinoma (pleural fluid) exon 19 del 2 2nd line Unavailable Unavailable 15.3
5 (5) 46 M Asian Never IV Squamous (R lung) exon 19 del Adenocarcinoma (SC LN) exon 19 del 1 1st line PR 5.0+ 6.6+
6 (6) 73 M White Former (25 PY) IV Squamous (adrenal) exon 19 del Adenocarcinoma (SC LN) insufficient 2 3rd line Unavailable Unavailable 29.8
7 (10) 58 M Asian Never IV Squamous (bronchus) L858R Squamous (T8) insufficient 1 1st line PR 1.9 2.5
8 (new) 76 M White Never IV* Squamous (R lung) insufficient Adenocarcinoma (L lung) exon 19 del 1 1st line PR 5.3 5.3+
9 (new) 68 M White Never IV Squamous (L lung) L858R None N/A 4 4th line PR 2.8+ 24.0+
10 (new) 30 F Asian Never IV Adenosquamous (R lung) L858R None N/A 2 1st line PR 8.4 10.9+
11 (new) 50 M White Never IV Adenosquamous (L lung) exon 19 del None N/A 1 1st line PR 9.2+ 9.6+
#

In parentheses are corresponding patient IDs in reference (8).

^

Biopsy numbers are not chronologic: biopsy #1 represents the index case (EGFR mutant “SQCLC”)

Stage at the time of TKI treatment.

*

Prior Stage IIA treated with induction cisplatin + pemetrexed followed by LLL lobectomy

Acquired resistance biopsy

Abbreviations: SC LN supraclavicular lymph node, PR partial response, SD stable disease, PY pack years